한글목차

황산 네오마이신 세계 시장은 2024년에 2억 4,680만 달러로 평가되며, 2030년에는 3억 8,205만 달러에 달할 것으로 예상되며, 5.22%의 CAGR로 성장할 것으로 예상됩니다.

광범위 아미노글리코사이드계 항생제인 황산 네오마이신은 인간과 동물의 세균 감염 치료에 널리 사용되고 있습니다. 그 효과, 저렴한 가격, 외용제 및 경구제로의 응용으로 인해 피부 질환 및 위장 질환과 같은 감염성 질환 관리에 선호되고 있습니다. 특히 깨끗한 물과 위생 시설에 대한 접근성이 제한적인 신흥국 시장에서 세균 감염이 증가하고 예방 의료에 대한 관심이 높아짐에 따라 시장이 확대되고 있습니다. 황산 네오마이신의 치료적 다양성과 비용 효율성은 제약 및 수의학 분야 모두에서 황산 네오마이신의 사용을 계속 지지하고 있습니다.

시장 촉진요인

헬스케어 산업의 성장

주요 시장 과제

부작용

주요 시장 동향

수의학 분야에서 황산 네오마이신에 대한 수요 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 황산 네오마이신 시장에 미치는 영향

제5장 세계의 황산 네오마이신 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 판매 채널별(직접, 간접)
  • 용도별(피부 감염증, 눈 감염증, 귀 감증염, 백신 제조, 수의학, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 황산 네오마이신 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 황산 네오마이신 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 황산 네오마이신 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 황산 네오마이신 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 황산 네오마이신 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 세계의 황산 네오마이신 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Pfizer Limited
• Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
• Myland Pharma Pvt Ltd
• Xi'an International Healthcare Factory Co., Ltd.
• Shandong Yifan Chemical Technology Co., Ltd.
• Xi'an Henrikang Biotech Co., Ltd.
• Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
• Jinyao Xinrui Pharmaceutical
• Xinyu Pharmaceutical
• Renfu Pharmaceutical

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

영문목차

The Global Neomycin Sulphate Market was valued at USD 246.80 million in 2024 and is projected to reach USD 382.05 million by 2030, growing at a CAGR of 5.22%. Neomycin sulphate, a broad-spectrum aminoglycoside antibiotic, is widely used to treat bacterial infections in both humans and animals. Its effectiveness, affordability, and application in topical and oral formulations make it a preferred choice in managing infections such as skin conditions and gastrointestinal disorders. The market is expanding due to rising incidences of bacterial infections and increased focus on preventive healthcare, especially in developing regions where limited access to clean water and sanitation persists. Neomycin sulphate's therapeutic versatility, combined with its cost-effectiveness, continues to support its use across both pharmaceutical and veterinary domains.

Key Market Drivers

Growth in Healthcare Industry

The ongoing expansion of the global healthcare industry is significantly driving demand for neomycin sulphate. With global healthcare generating over USD 4 trillion annually, the pharmaceutical and biotechnology segments alone account for approximately USD 850 billion. Neomycin sulphate plays a critical role in treating infections of the skin, eyes, and intestines, and is frequently used in both over-the-counter and prescription drugs. The growing burden of infectious diseases, especially in developing economies with inadequate sanitation infrastructure, reinforces the need for effective antimicrobials. Healthcare institutions rely heavily on neomycin sulphate for its broad-spectrum antibacterial capabilities, particularly in outpatient and surgical environments. As healthcare access improves globally, so does the reliance on reliable antibiotics like neomycin sulphate to manage and prevent infection-related complications.

Key Market Challenges

Adverse Side Effects

A major challenge in the global neomycin sulphate market is the potential for severe side effects associated with its prolonged or high-dose use. While effective, the antibiotic can cause nephrotoxicity and ototoxicity, leading to kidney damage and hearing loss. These risks have led to increased caution among healthcare providers and stricter regulatory oversight. As a result, neomycin sulphate usage is often limited to short-term or topical applications in human medicine. Meanwhile, the veterinary sector faces heightened scrutiny due to the risk of antibiotic residues in animal-derived products, which raises public health concerns. This has led to a gradual shift toward alternative antibiotics with better safety profiles.

Key Market Trends

Rising Demand of Neomycin Sulphate in Veterinary Sectors

A growing trend in the neomycin sulphate market is its increasing use in veterinary medicine. Chickens dominate global poultry production, comprising over 90% of the sector, followed by ducks, turkeys, guineafowl, and geese. As global demand for animal protein rises, so does the need for effective veterinary antibiotics. Neomycin sulphate is widely used to treat gastrointestinal and topical bacterial infections in livestock and poultry due to its proven efficacy against gram-negative bacteria. This trend is particularly pronounced in regions with large-scale animal farming operations, where maintaining animal health is essential for productivity and food safety.

Key Market Players

• Pfizer Limited
• Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
• Myland Pharma Pvt Ltd
• Xi'an International Healthcare Factory Co., Ltd.
• Shandong Yifan Chemical Technology Co., Ltd.
• Xi'an Henrikang Biotech Co., Ltd.
• Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
• Jinyao Xinrui Pharmaceutical
• Xinyu Pharmaceutical
• Renfu Pharmaceutical

Report Scope:

In this report, the Global Neomycin Sulphate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neomycin Sulphate Market, By Sales Channel:

• Direct
• Indirect

Neomycin Sulphate Market, By End Use:

• Skin Infection
• Eye Infection
• Ear Infection
• Vaccine Production
• Veterinary Medicine
• Others

Neomycin Sulphate Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neomycin Sulphate Market.

Available Customizations:

Global Neomycin Sulphate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Neomycin Sulphate Market

5. Global Neomycin Sulphate Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Skin Infection, Eye Infection, Ear Infection, Vaccine Production, Veterinary Medicine, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Neomycin Sulphate Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neomycin Sulphate Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Neomycin Sulphate Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Neomycin Sulphate Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Neomycin Sulphate Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Neomycin Sulphate Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Neomycin Sulphate Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Neomycin Sulphate Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Neomycin Sulphate Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Neomycin Sulphate Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Neomycin Sulphate Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Neomycin Sulphate Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Neomycin Sulphate Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Neomycin Sulphate Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Neomycin Sulphate Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Neomycin Sulphate Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Neomycin Sulphate Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neomycin Sulphate Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Neomycin Sulphate Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Neomycin Sulphate Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Neomycin Sulphate Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neomycin Sulphate Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Neomycin Sulphate Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Neomycin Sulphate Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Neomycin Sulphate Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Limited
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
• 15.3. Myland Pharma Pvt Ltd
• 15.4. Xi'an International Healthcare Factory Co., Ltd.
• 15.5. Shandong Yifan Chemical Technology Co., Ltd.
• 15.6. Xi'an Henrikang Biotech Co., Ltd.
• 15.7. Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
• 15.8. Jinyao Xinrui Pharmaceutical
• 15.9. Xinyu Pharmaceutical
• 15.10. Renfu Pharmaceutical

16. Strategic Recommendations

17. About Us & Disclaimer